BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:KESHO
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20260312T190000
DTEND;TZID=Africa/Nairobi:20260312T203000
DTSTAMP:20260527T042458
CREATED:20260310T140249Z
LAST-MODIFIED:20260319T174323Z
UID:41385-1773342000-1773347400@kesho-kenya.org
SUMMARY:Multiple Myeloma Care in Western Kenya
DESCRIPTION:[vc_row][vc_column][vc_column_text css=””]Event Title: The Journey of Multiple Myeloma Care in Western Kenya \nAccreditation: CPD Accredited \n\nDate: 12th March 2026\nTime: 7 PM – 8:30 PM EAT\nOrganization: KESHO (Kenya Society of Haematology & Oncology)\n\nModerator:  \n\nDr. Matilda Ongondi: Consultant Physician and Clinical Haemato-Oncologist\, Kenyatta National Hospital.\n\nSpeakers \n\n\n\n\nDr. Teresa Lotodo: Senior Lecturer & Consultant Pathologist (AP/CP)Topic: Modern Diagnostic Paradigms in Multiple Myeloma: From Morphology to Molecular Risk Stratification \nDr. Rohini Radia: Consultant in BMT and HaematologyTopic: Contemporary Management of Multiple Myeloma: Sequencing\, Cellular Therapies and Risk-Adapted Strategies \nDr. Beatrice Melly: Clinical Haematologist\, Moi Teaching and Referral HospitalTopic: Building Sustainable Myeloma Care Pathways: Access\, Infrastructure and Multidisciplinary Integration \nHightlights\n\n\n\n\n\n\n\n\nThis session examined how multiple myeloma care is evolving within the Kenyan context\, bringing together perspectives on diagnostics\, treatment advances and system-level delivery. \nA central theme was the contrast between rapid global therapeutic progress and the realities of access and infrastructure in low- and middle-income settings. While survival outcomes have improved significantly with the introduction of proteasome inhibitors\, immunomodulatory agents and anti-CD38 therapies\, translating these gains into routine practice remains uneven. \nThe discussion highlighted the importance of accurate and timely diagnosis\, with a shift from morphology-based approaches towards molecular and cytogenetic risk stratification to guide treatment decisions. \nFrom a clinical perspective\, modern management is increasingly risk-adapted\, incorporating quadruplet induction regimens\, autologous stem cell transplantation and maintenance strategies. Emerging therapies\, including CAR-T cells and bispecific antibodies are redefining outcomes in relapsed disease\, though access remains limited in many settings. \nAt a systems level\, the AMPATH multiple myeloma program was presented as a model of how coordinated care can be built through partnerships\, integrating clinical care\, training and research within a learning health system. The approach emphasizes improving access\, strengthening diagnostic and treatment infrastructure\, and embedding multidisciplinary care pathways to support patients across the disease course. \nAcross the session\, a consistent message emerged: advancing myeloma care requires not only better therapies\, but systems capable of delivering them. \nKey Takeaways \n\nMyeloma outcomes are improving with novel and combination therapies.\nAccurate diagnosis and risk stratification are central to management.\nStandard care includes quadruplet induction\, ASCT and maintenance therapy.\nCAR-T and bispecific antibodies are reshaping relapsed disease care.\nSustainable progress depends on access\, infrastructure and integrated care models.
URL:https://kesho-kenya.org/event/multiple-myeloma-care-in-western-kenya/
CATEGORIES:CME 2026,Conferences,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2026/03/WhatsApp-Image-2026-03-10-at-11.40.58-AM-1-e1773151318490.jpeg
END:VEVENT
END:VCALENDAR